Список литературы

1. Packham G., Stevenson F. The role of the B-cell receptor in the pathogenesis of chronic lymphocytic leukaemia//Seminars in Cancer Biology. 2010. Vol. 20, N 6. P. 391 - 399.

2. Vardi A. et al. Immunogenetic studies of chronic lymphocytic leukemia: Revelations and speculations about ontogeny and clinical evolution//Cancer Research. American Association for Cancer Research Inc., 2014. Vol. 74, N 16. P. 4211 - 4216.

3. Murray F. et al. Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: Implications for the role of antigen selection in leukemogenesis//Blood. 2008. Vol. 111, N 3. P. 1524 - 1533.

4. Strati P., Shanafelt T.D. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: Diagnosis, natural history, and risk stratification//Blood. American Society of Hematology, 2015. Vol. 126, N 4. P. 454 - 462.

5. Zhang S., Kipps T.J. The Pathogenesis of Chronic Lymphocytic Leukemia//Annu. Rev. Pathol. Mech. Dis. 2014. Vol. 9, N 1. P. 103 - 118.

6. Burger J.A., Chiorazzi N. B cell receptor signaling in chronic lymphocytic leukemia//Trends in Immunology. 2013. Vol. 34, N 12. P. 592 - 601.

7. Morton L.M. et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992 - 2001//Blood. 2006. Vol. 107, N 1. P. 265 - 276.

8. Watson L., Wyld P., Catovsky D. Disease burden of chronic lymphocytic leukaemia within the European Union//Eur. J. Haematol. 2008. Vol. 81, N 4. P. 253 - 258.

9. Jemal A. et al. Cancer statistics, 2007.//CA. Cancer J. Clin. 2007. Vol. 57, N 1. P. 43 - 66.

10. Dores G.M. et al. Chronic lymphocytic leukaemia and small lymphocytic lymphoma: Overview of the descriptive epidemiology//Br. J. Haematol. 2007. Vol. 139, N 5. P. 809 - 819.

11. Злокачественные новообразования в России в 2017 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ "НМИЦ радиологии" Минздрава России, 2018.

12. Hallek M. et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL//Blood. American Society of Hematology, 2018. Vol. 131, N 25. P. 2745 - 2760.

13. Armitage J.O. Staging Non-Hodgkin Lymphoma//CA. Cancer J. Clin. Wiley, 2005. Vol. 55, N 6. P. 368 - 376.

14. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data//Lancet Oncol. Lancet Publishing Group, 2016. Vol. 17, N 6. P. 779 - 790.

15. Swerdlow S.H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms//Blood. 2016.

16. Никитин Е.А. et al. Хронический лимфолейкоз.//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 179 - 200.

17. Morice W.G. et al. Predictive value of blood and bone marrow flow cytometry in B-cell lymphoma classification: Comparative analysis of flow cytometry and tissue biopsy in 252 patients//Mayo Clin. Proc. Elsevier Ltd, 2008. Vol. 83, N 7. P. 776 - 785.

18. Rawstron A.C. et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia//N. Engl. J. Med. Massachussetts Medical Society, 2008. Vol. 359, N 6. P. 575 - 583.

19. Molica S., Giannarelli D., Montserrat E. Minimal Residual Disease and Survival Outcomes in Patients With Chronic Lymphocytic Leukemia: A Systematic Review and Meta-analysis.//Clin. Lymphoma. Myeloma Leuk. 2019. Vol. 19, N 7. P. 423 - 430.

20. Rossi D. et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among patients with chronic lymphocytic leukemia//Leuk. Lymphoma. 2009. Vol. 50, N 4. P. 604 - 611.

21. Conte M.J. et al. Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma//Leuk. Lymphoma. Informa Healthcare, 2014. Vol. 55, N 9. P. 2079 - 2084.

22. Parikh S.A., Kay N.E., Shanafelt T.D. How we treat Richter syndrome.//Blood. 2014. Vol. 123, N 11. P. 1647 - 1657.

23. Hallek M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial//Lancet. Lancet Publishing Group, 2010. Vol. 376, N 9747. P. 1164 - 1174.

24. Fischer K. et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: Updated results of the CLL8 trial//Blood. American Society of Hematology, 2016. Vol. 127, N 2. P. 208 - 215.

25. Fischer K. et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: A multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group//J. Clin. Oncol. 2012. Vol. 30, N 26. P. 3209 - 3216.

26. Eichhorst B. et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial//Lancet Oncol. Lancet Publishing Group, 2016. Vol. 17, N 7. P. 928 - 942.

27. Shanafelt T., Wang V., Kay N. A randomized phase III study of ibrutinib (PCI-32765)-based therapy vs. standard fludarabine, cyclophosphamide, and rituximab (FCR) chemoimmunotherapy in untreated younger patients with chronic lymphocytic leukemia (CLL): a trial of the ECOG-ACRIN Cancer//ASH Annual Meeting. 2018. P. LBA-4.

28. Burger J.A. et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.//Blood. 2019. Vol. 133, N 10. P. 1011 - 1019.

29. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. 2019.

30. Assouline S. et al. Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial.//Lancet. Haematol. 2016. Vol. 3, N 3. P. e128 - 38.

31. Goede V. et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions//N. Engl. J. Med. Massachussetts Medical Society, 2014. Vol. 370, N 12. P. 1101 - 1110.

32. Michallet A.S. et al. Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: Primary analysis of the randomized, open-label mable study//Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 4. P. 698 - 706.

33. Burger J.A. et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia//N. Engl. J. Med. Massachussetts Medical Society, 2015. Vol. 373, N 25. P. 2425 - 2437.

34. Burger J.A. et al. Ibrutinib for First-Line Treatment of Older Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): A 4-Year Experience From the REASONATE-2 Study//EHA 23 Proceedings. 2018. P. Abstract PF343.

35. Woyach J.A. et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.//N. Engl. J. Med. 2018. Vol. 379, N 26. P. 2517 - 2528.

36. Nikitin E. Randomised Comparison Of FCR-Lite And ClbR (Chlorambucil Plus Rituximab) Regimens In Elderly Patients With Chronic Lymphocytic Leukemia//EHA 18 Proceedings. 2013. P. Abstract NS1147.

37. R. et al. Chlorambucil plus rituximab with or without maintenance rituximab as first-line treatment for elderly chronic lymphocytic leukemia patients//Am. J. Hematol. Wiley-Liss Inc., 2014. Vol. 89, N 5. P. 480 - 486.

38. Hillmen P. et al. Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study//J. Clin. Oncol. American Society of Clinical Oncology, 2014. Vol. 32, N 12. P. 1236 - 1241.

39. Fischer K. et al. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions.//N. Engl. J. Med. 2019. Vol. 380, N 23. P. 2225 - 2236.

40. Jones J.A. et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial.//Lancet. Oncol. 2018. Vol. 19, N 1. P. 65 - 75.

41. Catovsky D., Else M., Richards S. Chlorambucil-still not bad: A reappraisal//Clinical Lymphoma, Myeloma and Leukemia. Elsevier Inc., 2011. Vol. 11, N SUPPL.1. P. S2.

42. Hainsworth J.D. et al. Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the Minnie Pearl Cancer Research Network//J. Clin. Oncol. 2003. Vol. 21, N 9. P. 1746 - 1751.

43. Michallet A.-S. et al. Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.//Am. J. Hematol. 2017. Vol. 92, N 6. P. E105 - E107.

44. Burger J.A. et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: A single-arm, phase 2 study//Lancet Oncol. Lancet Publishing Group, 2014. Vol. 15, N 10. P. 1090 - 1099.

45. Sorror M.L. et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning//J. Clin. Oncol. 2008. Vol. 26, N 30. P. 4912 - 4920.

46. Dreger P. et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: Long-term clinical and MRD results of the German CLL Study Group CLL3X trial//Blood. 2010. Vol. 116, N 14. P. 2438 - 2447.

47. Stilgenbauer S. et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study//Lancet Oncol. Lancet Publishing Group, 2016. Vol. 17, N 6. P. 768 - 778.

48. Tam C.S. et al. Life After FCR: Outcomes of patients with chronic lymphocytic leukemia who progress after frontline treatment with Fludarabine, Cyclophosphamide and Rituximab.//Blood. 2014. P. 3059 - 3064.

49. Fischer K. et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: A Multicenter Phase II trial of the German Chronic Lymphocytic Leukemia Study Group//J. Clin. Oncol. 2011. Vol. 29, N 26. P. 3559 - 3566.

50. Byrd J.C. et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.//N. Engl. J. Med. 2014. Vol. 371, N 3. P. 213 - 223.

51. Moreno C. et al. Ibrutinib in previously treated chronic lymphocytic leukemia: updated efficacy and safety of the RESONATE study with up to four years of follow-up//EHA 22 Proceedings. 2017. P. Abstract S769.

52. Chanan-Khan A. et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): A randomised, double-blind, phase 3 study//Lancet Oncol. Lancet Publishing Group, 2016. Vol. 17, N 2. P. 200 - 211.

53. Hallek M. et al. Three-year follow-up of patients with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) receiving ibrutinib plus bendamustine and rituximab (BR) versus placebo plus BR: an update of the HELIOS study.//Leuk. Lymphoma. 2017. Vol. 58. P. 192 - 194.

54. Seymour J.F. et al. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.//N. Engl. J. Med. 2018. Vol. 378, N 12. P. 1107 - 1120.

55. Castro J.E. et al. Rituximab in combination with high-dose methylprednisolone for the treatment of chronic lymphocytic leukemia//Leukemia. Nature Publishing Group, 2009. Vol. 23, N 10. P. 1779 - 1789.

56. Raanani P. et al. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis.//Leuk. Lymphoma. 2009. Vol. 50, N 5. P. 764 - 772.

57. Константинова Т.С., Клясова Г.А., Капланов К.Д. Лечение и профилактика инфекционных осложнений у пациентов с лимфопролиферативными заболеваниями.//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 289 - 311.

58. Rubin L.G. et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.//Clin. Infect. Dis. 2014. Vol. 58, N 3. P. 309 - 318.

59. Sinisalo M. et al. Response to vaccination against different types of antigens in patients with chronic lymphocytic leukaemia.//Br. J. Haematol. 2001. Vol. 114, N 1. P. 107 - 110.

60. Абузарова Г.Р. et al. Обезболивание взрослых и детей при оказании медицинской помощи. Методические рекомендации. ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России, 2016. 94 p.

61. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных//Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 278 - 288.

62. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies.//Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

63. Reda G. et al. Secondary Malignancies in Chronic Lymphocytic Leukemia: A Single Centre Retrospective Analysis of 514 Cases//Blood. 2015. Vol. 126, N 23.

64. Beiggi S. et al. Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study.//Br. J. Cancer. 2013. Vol. 109, N 5. P. 1287 - 1290.

65. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group//Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.

66. Linn B.S., Linn M.W., Gurel L. Cumulative illness rating scale//J. Am. Geriatr. Soc. 1968. Vol. 16, N 5. P. 622 - 626.